Mark Cuban's drug company, drug maker team up for super-cheap version of Humira
Mark Cuban Cost Plus Drug Co. will offer a cut-rate biosimilar version of one of the best-selling drugs developed by Peninsula drug maker Coherus BioSciences Inc. The price comes in at near the original price for the rheumatoid arthritis drug when it was introduced more than 20 years ago. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 2, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Coherus BioSciences And Mark Cuban ’s Drug Company Aim To Disrupt Humira-Referenced Biosimilar Space With Launch Of Yusimry At A 85% Discount
Coherus BioSciences and Mark Cuban ’s Cost Plus Drug Company will shake up the Humira and Humira-referenced biosimilar space with the launch of Yusimry at a 85% discount. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 2, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Mark Cuban company, Peninsula drug maker Coherus team up for super-cheap version of Humira
The price for Coherus' biosimilar version of Humira comes in at near the original price for the rheumatoid arthritis drug when it was introduced more than 20 years ago. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 1, 2023 Category: American Health Authors: Ron Leuty Source Type: news

AbbVie's Rinvoq passes midstage test in systemic lupus erythematosus, heads into phase 3
AbbVie's Rinvoq is delivering blockbuster sales and driving growth for the drugmaker after its January loss of exclusivity for top-selling Humira. | AbbVie's Rinvoq has been picking up FDA approvals left and right in recent years. Now it's showing its worth in systemic lupus erythematosus.#abbvie #rinvoq #humira #fda (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2023 Category: Consumer Health News Source Type: news

AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients
Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.MDedge News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 25, 2023 Category: Gastroenterology Tags: Rheumatology News Source Type: news

FDA Approves Yuflyma (adalimumab-aaty), a Biosimilar to Humira
JERSEY CITY, N.J.--(BUSINESS WIRE) May 24, 2023 --Celltrion USA today announced that the U.S. Food and Drug Administration (FDA) has approved Yuflyma® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 24, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Approves Yuflyma as Ninth Adalimumab Biosimilar FDA Approves Yuflyma as Ninth Adalimumab Biosimilar
The manufacturer, Celltrion, is also seeking an interchangeability designation from the FDA, which is tentatively expected in the fourth quarter of 2024.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 24, 2023 Category: Internal Medicine Tags: Rheumatology News Alert Source Type: news

FDA Approves Autoinjector Pen for Humira Biosimilar, Cyltezo FDA Approves Autoinjector Pen for Humira Biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 22, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news

US FDA Approves the Cyltezo Pen, a New Autoinjector Option, Ahead of July 1 Commercial Launch
RIDGEFIELD, Conn., May 22, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2023 Category: Drugs & Pharmacology Source Type: news

What To Expect After The Failed AbbVie Drug Sales (NYSE:ABBV)
On April 27, 2023, AbbVie (NYSE:ABBV) released its Q1 2023 financial results. In recent quarters, sales of the company's products have shown mixed dynamics, which led to falling short of Wall Street analysts' expectations. So, AbbVie's revenue amounted to $12,225 million in the first three months…#abbvie #richardgonzalez #humira #tnf #amjevita #amgen #amgn #fda #boehringeringelheim #skyriziandrinvoq (Source: Reuters: Health)
Source: Reuters: Health - April 30, 2023 Category: Consumer Health News Source Type: news

AbbVie's Humira Downfall Is Swift As Biosimilars Hammer Away At Sales
stock crumbled Thursday after the first approved biosimilar copycat to launch in the U.S. hammered away at Humira's legendary sales. X Though Amgen's (AMGN) biosimilar, dubbed Amjevita, launched halfway through the first quarter, global sales of immunology blockbuster Humira slumped more than 25%…#humira #amgen #amgn #rickgonzalez #abbvie #rinvoq #leebrown #thirdbridge #robmichael #marketsmithcom (Source: Reuters: Health)
Source: Reuters: Health - April 29, 2023 Category: Consumer Health News Source Type: news

Adalimumab + Methotrexate Beneficial for Pediatric Crohn Disease
THURSDAY, April 27, 2023 -- For pediatric Crohn disease (PCD) patients, treatment with methotrexate combined with adalimumab, but not infliximab, is associated with a reduction in treatment failure, according to a study published online March 31 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 27, 2023 Category: Pharmaceuticals Source Type: news

With Humira exclusivity gone, AbbVie struggles in the first quarter
Global sales of AbbVie's flagship arthritis drug fell more than 25% after rival drugmakers were allowed to sell nearly identical products. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 27, 2023 Category: American Health Authors: Ben Miller Source Type: news

AbbVie: The Tsunami Heading Towards Investors
AbbVie (NYSE:ABBV) focuses on discovering, developing, and marketing branded therapeutics protected by intellectual property rights, allowing it to command higher prices and margins. However, once the exclusivity expires (usually after 15-20 years), other companies can produce and sell generic…#abbv #abbottlaboratories #abt #humira #onceamgen #amgn #amgevita #fda #amgen #mylan (Source: Reuters: Health)
Source: Reuters: Health - April 14, 2023 Category: Consumer Health News Source Type: news

Pediatric Crohn's: Adalimumab+Methotrexate Offers Strong Benefit Pediatric Crohn's: Adalimumab+Methotrexate Offers Strong Benefit
A landmark trial suggests adding low-dose methotrexate should be strongly considered in children with Crohn ' s disease who are starting adalimumab.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - April 14, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news